Baseline characteristics (N = 38)
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 64 (47-81) |
| Male:female | 25:13 |
| Rai stage at screening | |
| 0 | 3 |
| I-II | 21 |
| III-IV | 9 |
| Missing | 5 |
| IGHV, n/N (%) | |
| Unmutated | 27/34 (79) |
| Mutated | 7/34 (21) |
| FISH (according to Döhner hierarchical model), n/N (%) | |
| del(17p) | 7/33 (21) |
| del(11q) | 9/32 (28) |
| Trisomy 12 | 0/33 (0) |
| Normal | 8/32 (25) |
| del(13q) | 9/33 (27) |
| TP53 mutation, n/N (%) | 9/31 (29) |
| Median no. of prior therapies (range) | 1 (1-7) |
| Type of prior therapies, n/N (%) | |
| Fludarabine, cyclophosphamide ± rituximab | 23/38 (60.5) |
| Bendamustine + rituximab | 17/38 (45) |
| Chlorambucil ± anti-CD20 monoclonal antibody | 7/38 8 (18) |
| Phosphatidylinositol 3-kinase inhibitor (idelalisib, duvelisib) | 5/38 (13) |
| TLS risk, n/N (%) | |
| Low | 6/38 (16) |
| Medium | 18/38 (47) |
| High | 14/38 (37) |
| Median ALC count (×109/L) at screening (range) | 97.6 (3.5-208.4) |
| ALC ≥ 25 × 109/L at screening, n/N (%) | 26/38 (68) |
| Lymph node size at screening | |
| ≥5 cm | 16 |
| ≥10 cm | 8 |
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 64 (47-81) |
| Male:female | 25:13 |
| Rai stage at screening | |
| 0 | 3 |
| I-II | 21 |
| III-IV | 9 |
| Missing | 5 |
| IGHV, n/N (%) | |
| Unmutated | 27/34 (79) |
| Mutated | 7/34 (21) |
| FISH (according to Döhner hierarchical model), n/N (%) | |
| del(17p) | 7/33 (21) |
| del(11q) | 9/32 (28) |
| Trisomy 12 | 0/33 (0) |
| Normal | 8/32 (25) |
| del(13q) | 9/33 (27) |
| TP53 mutation, n/N (%) | 9/31 (29) |
| Median no. of prior therapies (range) | 1 (1-7) |
| Type of prior therapies, n/N (%) | |
| Fludarabine, cyclophosphamide ± rituximab | 23/38 (60.5) |
| Bendamustine + rituximab | 17/38 (45) |
| Chlorambucil ± anti-CD20 monoclonal antibody | 7/38 8 (18) |
| Phosphatidylinositol 3-kinase inhibitor (idelalisib, duvelisib) | 5/38 (13) |
| TLS risk, n/N (%) | |
| Low | 6/38 (16) |
| Medium | 18/38 (47) |
| High | 14/38 (37) |
| Median ALC count (×109/L) at screening (range) | 97.6 (3.5-208.4) |
| ALC ≥ 25 × 109/L at screening, n/N (%) | 26/38 (68) |
| Lymph node size at screening | |
| ≥5 cm | 16 |
| ≥10 cm | 8 |
FISH, fluorescence in situ hybridization.